KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Ken Kato, Manish A. Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong Mu Sun, Byoung Chul Cho, Mustafa Özgüroǧlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

Original languageEnglish
Pages (from-to)1057-1066
Number of pages10
JournalFuture Oncology
Volume15
Issue number10
DOIs
Publication statusPublished - 2019 Apr

Fingerprint

Esophagogastric Junction
Esophageal Neoplasms
Drug Therapy
Neoplasms
Combination Drug Therapy
Platinum
Registries
Therapeutics
Placebos
Clinical Trials
Guidelines
pembrolizumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., ... Doi, T. (2019). KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 15(10), 1057-1066. https://doi.org/10.2217/fon-2018-0609
Kato, Ken ; Shah, Manish A. ; Enzinger, Peter ; Bennouna, Jaafar ; Shen, Lin ; Adenis, Antoine ; Sun, Jong Mu ; Cho, Byoung Chul ; Özgüroǧlu, Mustafa ; Kojima, Takashi ; Kostorov, Vladimir ; Hierro, Cinta ; Zhu, Ying ; McLean, Lee Anne ; Shah, Sukrut ; Doi, Toshihiko. / KEYNOTE-590 : Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. In: Future Oncology. 2019 ; Vol. 15, No. 10. pp. 1057-1066.
@article{2940d087656e4e7886367807ce57b55e,
title = "KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer",
abstract = "Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.",
author = "Ken Kato and Shah, {Manish A.} and Peter Enzinger and Jaafar Bennouna and Lin Shen and Antoine Adenis and Sun, {Jong Mu} and Cho, {Byoung Chul} and Mustafa {\"O}zg{\"u}roǧlu and Takashi Kojima and Vladimir Kostorov and Cinta Hierro and Ying Zhu and McLean, {Lee Anne} and Sukrut Shah and Toshihiko Doi",
year = "2019",
month = "4",
doi = "10.2217/fon-2018-0609",
language = "English",
volume = "15",
pages = "1057--1066",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "10",

}

Kato, K, Shah, MA, Enzinger, P, Bennouna, J, Shen, L, Adenis, A, Sun, JM, Cho, BC, Özgüroǧlu, M, Kojima, T, Kostorov, V, Hierro, C, Zhu, Y, McLean, LA, Shah, S & Doi, T 2019, 'KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer', Future Oncology, vol. 15, no. 10, pp. 1057-1066. https://doi.org/10.2217/fon-2018-0609

KEYNOTE-590 : Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. / Kato, Ken; Shah, Manish A.; Enzinger, Peter; Bennouna, Jaafar; Shen, Lin; Adenis, Antoine; Sun, Jong Mu; Cho, Byoung Chul; Özgüroǧlu, Mustafa; Kojima, Takashi; Kostorov, Vladimir; Hierro, Cinta; Zhu, Ying; McLean, Lee Anne; Shah, Sukrut; Doi, Toshihiko.

In: Future Oncology, Vol. 15, No. 10, 04.2019, p. 1057-1066.

Research output: Contribution to journalArticle

TY - JOUR

T1 - KEYNOTE-590

T2 - Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

AU - Kato, Ken

AU - Shah, Manish A.

AU - Enzinger, Peter

AU - Bennouna, Jaafar

AU - Shen, Lin

AU - Adenis, Antoine

AU - Sun, Jong Mu

AU - Cho, Byoung Chul

AU - Özgüroǧlu, Mustafa

AU - Kojima, Takashi

AU - Kostorov, Vladimir

AU - Hierro, Cinta

AU - Zhu, Ying

AU - McLean, Lee Anne

AU - Shah, Sukrut

AU - Doi, Toshihiko

PY - 2019/4

Y1 - 2019/4

N2 - Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

AB - Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov: NCT03189719.

UR - http://www.scopus.com/inward/record.url?scp=85064212073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064212073&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0609

DO - 10.2217/fon-2018-0609

M3 - Article

C2 - 30735435

AN - SCOPUS:85064212073

VL - 15

SP - 1057

EP - 1066

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 10

ER -